(800) 429-3205

Submit Your Information for the Organon & Co. Lawsuit

Lead plaintiff deadline is July 22, 2025.

If you purchased or acquired Organon & Co. securities between November 3, 2022 through April 30, 2025, please contact Berger Montague using the form below.

Please view our terms of use policy and our privacy policy.

First Name *

Last Name *

Email *

Phone Number *

Address

City

Zip

State

Are you a current or former employee of Organon & Co. ?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

Terms of Use *

I agree to the terms of service

Subscribe

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

About the Lawsuit

According to the lawsuit, despite the increase in debt from the Dermavant acquisition, the Company assured investors that it would maintain its dividend, which it described as its “#1 capital allocation priority.” The suit alleges that, notwithstanding such representations, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt.

In addition, the lawsuit alleges that defendants failed to disclose that Organon faced a higher risk of loss of exclusivity and price erosion as to Nexplanon. Thus, Nexplanon sales growth was not as strong as defendants represented and would not reach $1 billion by the end of fiscal year 2025. As a result, Organon was likely not on track to achieve the $1 billion milestone payment from Merck & Co. on its Nexplanon sales.

On May 1, 2025, investors learned the truth when Organon announced that management reset the Company’s dividend payout from $0.28 per share to $0.02 per share. Organon’s senior management explained that the Company had “reset our capital allocation priorities to accelerate progress towards deleveraging” and that “returning capital to shareholders is right now, less of a priority.”

On this news, the price of Organon stock declined $3.48 per share – approximately 27% – from a closing price of $12.93 per share on April 30, 2025 to a close of $9.45 per share on May 1, 2025.

Investors who purchased or acquired Organon securities between November 3, 2022 through April 30, 2025, may no later than July 22, 2025, seek to be appointed as a lead plaintiff representative of the class.